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Glioblastoma (GB) is a highly infiltrative tumor recurring within a few centimeters
of the resection cavity in 85 % of cases, even in cases of complete tumor resection
and adjuvant chemo/radiotherapy. We recently isolated GB-associated stromal cells
(GASCs) from the GB peritumoral zone, with phenotypic and functional properties
similar to those of the cancer-associated fibroblasts present in the stroma of
carcinomas. In particular, GASCs promote blood vessel development and have
tumor-promoting effects on glioma cells in vitro and in vivo. In this study, we
characterized these cells further, by analyzing the transcriptome and methylome of
14 GASC and five control stromal cell preparations derived from non-GB peripheral
brain tissues. We identified two subtypes of GASCs in surgical margins in GB
patients: GASC-A and GASC-B. GASC-B promoted the development of tumors and
endothelium, whereas GASC-A did not. A difference in DNA methylation may
underlie these two subtypes. We identified various proteins as being produced in
the procarcinogenic GASC-B. Some of these proteins may serve as prognostic
factors for GB and/or targets for anti-glioma treatment. In conclusion, in this era of
personalized therapy, the status of GASCs in GB-free surgical margins should be
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